<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762875</url>
  </required_header>
  <id_info>
    <org_study_id>145-ADS-202</org_study_id>
    <nct_id>NCT04762875</nct_id>
  </id_info>
  <brief_title>MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies</brief_title>
  <official_title>A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination With Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Magenta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Magenta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study tests a new medicine for mobilizing stem cells so they can be collected&#xD;
      and used for allogeneic stem cell transplant for treatment of hematological malignancies.&#xD;
      MGTA-145, the new medicine, will be given with plerixafor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, open-label, multicenter, prospective study of MGTA-145 + plerixafor&#xD;
      mobilized HLA-matched sibling and matched unrelated donor allografts for myeloablative&#xD;
      hematopoietic stem cell transplantation (HSCT) in recipients with hematological malignancies.&#xD;
      Donors will undergo 1 or 2 days of mobilization and apheresis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HSC Yield in apheresis product</measure>
    <time_frame>Up to 2 days</time_frame>
    <description>To assess the efficacy of MGTA-145 in combination with plerixafor in mobilizing adequate number of hematopoietic stem cells (≥ 2.0 x 10^6 CD34+ cells/kg) in healthy donors in one apheresis setting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HSC Yield in apheresis product</measure>
    <time_frame>Up to 2 days</time_frame>
    <description>To determine the proportion of donors whose cells can be successfully mobilized and collected with a target CD34+ cell dose of at least 4.0 x 10^6 CD34+ cells/kg actual recipient weight in one apheresis collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events experienced by donors</measure>
    <time_frame>Baseline though day 180</time_frame>
    <description>To ascertain the incidence of adverse events (AEs) before and during apheresis experienced by donors receiving MGTA-145 + plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion related toxicities</measure>
    <time_frame>Baseline though 72 hours post donation</time_frame>
    <description>To ascertain the severity of adverse events (AEs) before and during apheresis experienced by donors receiving MGTA-145 + plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil and platelet engraftment</measure>
    <time_frame>Day 28, 56, 100, 180, 365</time_frame>
    <description>To determine the incidence of and kinetics of neutrophil and platelet recovery after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Durability</measure>
    <time_frame>Day 28, 56, 100, 180, 365</time_frame>
    <description>The proportion of participants with primary and secondary graft failure after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus host disease (GVHD)</measure>
    <time_frame>Day 21, 28, 56, 100, 180, and 365</time_frame>
    <description>To determine the incidence and severity of acute and chronic graft versus host disease (GVHD) after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>Day 21, 28, 56, 100, 180, and 365</time_frame>
    <description>To determine the proportion of treatment-related mortality and disease relapse/progression after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Day 21, 28, 56, 100, 180, and 365</time_frame>
    <description>To determine the probability of progression-free survival after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Day 21, 28, 56, 100, 180, and 365</time_frame>
    <description>To determine the probability of overall survival after transplantation of hematopoietic cells mobilized with MGTA-145 + plerixafor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events related to Allograft</measure>
    <time_frame>Day 0 through 365</time_frame>
    <description>To characterize the adverse effects experienced by recipients receiving grafts mobilized by MGTA-145 + plerixafor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Related Donors Donating PBSC to a Family Member</condition>
  <condition>Healthy Donors</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Single dose MGTA-145 plus plerixafor followed by apheresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGTA-145 in combination with plerixafor followed by apheresis on one or two consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGTA-145</intervention_name>
    <description>MGTA-145 will be be administered as an IV infusion</description>
    <arm_group_label>Single dose MGTA-145 plus plerixafor followed by apheresis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>240 µg/kg subcutaneously</description>
    <arm_group_label>Single dose MGTA-145 plus plerixafor followed by apheresis</arm_group_label>
    <other_name>Mozobil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Donor Inclusion Criteria:&#xD;
&#xD;
          -  Donor medical suitability and eligibility will be determined following Institution or&#xD;
             NMDP/Be The Match standards&#xD;
&#xD;
          -  Age 18-65 years old at the time of signing informed consent&#xD;
&#xD;
          -  8/8 (HLA- A, B, C, and DRB1) HLA-matched sibling or volunteer unrelated donor&#xD;
&#xD;
          -  Fulfill Institution or NMDP/Be The Match criteria to serve as a mobilized blood cell&#xD;
             donor&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 x institution upper limit of normal (ULN) or estimated&#xD;
             creatinine clearance (CRCL) &gt; 50 mL/min using the Modification of Diet in Renal&#xD;
             Disease Study (MDRD) equation or similar method&#xD;
&#xD;
        Recipient Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years old at the time of signing informed consent&#xD;
&#xD;
          -  Has an available 8/8 (HLA- A, B, C, and DRB1) HLA-matched sibling or volunteer&#xD;
             unrelated donor willing to donate peripheral blood stem cells (PBSC) for transplant&#xD;
&#xD;
          -  Fulfill additional individual Transplant Center Criteria for transplant beyond NMDP/Be&#xD;
             The Match criteria&#xD;
&#xD;
          -  One of the following diagnoses:&#xD;
&#xD;
               -  Acute myelogenous leukemia (AML) in 1st remission or beyond with ≤ 5% marrow&#xD;
                  blasts and no circulating blasts. Documentation of bone marrow assessment will be&#xD;
                  accepted within 45 days prior to the date of consent.&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL) in 1st remission or beyond with ≤ 5% marrow&#xD;
                  blasts and no circulating blasts. Documentation of bone marrow assessment will be&#xD;
                  accepted within 45 days prior to the date of consent.&#xD;
&#xD;
               -  Patients with myelodysplasia (MDS) with no circulating blasts and with less than&#xD;
                  10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack&#xD;
                  of differences in outcomes with &lt; 5% or 5-10% blasts in MDS). Documentation of&#xD;
                  bone marrow assessment will be accepted within 45 days prior to the date of&#xD;
                  consent.&#xD;
&#xD;
          -  Cardiac function: Left ventricular ejection fraction at least 45% based on most recent&#xD;
             echocardiogram or MUGA results obtained via standard of care&#xD;
&#xD;
          -  Estimated creatinine clearance acceptable per local institutional guidelines&#xD;
&#xD;
          -  Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO)&#xD;
             corrected for hemoglobin at least 50% and forced expiratory volume in first second&#xD;
             (FEV1) predicted at least 50% based on most recent DLCO results obtained via standard&#xD;
             of care&#xD;
&#xD;
          -  Liver function acceptable per local institutional guidelines&#xD;
&#xD;
          -  Karnofsky performance status (KPS) of 70% or greater&#xD;
&#xD;
          -  Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score of 4 or less&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          -  Donor unwilling or unable to give informed consent, or unable to comply with the&#xD;
             protocol including required follow-up and testing&#xD;
&#xD;
          -  Donor already enrolled on another investigational agent study&#xD;
&#xD;
          -  Pregnant or breastfeeding females, sexually active female and male donors not willing&#xD;
             or able to use adequate contraception, or males who do not agree to refrain from&#xD;
             donating sperm, from the time of consent through 3 months after treatment with&#xD;
             MGTA-145 + plerixafor&#xD;
&#xD;
        Recipient Exclusion Criteria:&#xD;
&#xD;
          -  Subject unwilling or unable to give informed consent, or unable to comply with the&#xD;
             protocol including required follow-up and testing&#xD;
&#xD;
          -  Subject whose donor does not meet the eligibility criteria and is a screen fail&#xD;
&#xD;
          -  Subjects with a prior allogeneic transplant&#xD;
&#xD;
          -  Subjects with active, uncontrolled infection at the time of the transplant preparative&#xD;
             regimen&#xD;
&#xD;
          -  Pregnant or breastfeeding females, sexually active female or male subjects not willing&#xD;
             or able to use adequate contraception, or males who do not agree to refrain from&#xD;
             donating sperm, from the time of consent through 3 months after PBSC infusion&#xD;
&#xD;
          -  Subjects with clinical evidence of active Central Nervous System (CNS) tumor&#xD;
             involvement as evidenced by documented disease on examination of spinal fluid or MRI&#xD;
             within 45 days of start of conditioning&#xD;
&#xD;
          -  A condition, which, in the opinion of the clinical investigator, would interfere with&#xD;
             the evaluation of primary and secondary endpoints&#xD;
&#xD;
          -  Planned treatment with a new investigational agent from the time of transplant through&#xD;
             30 days post-transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Devine, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Marrow Donor Program</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alisha Mussetter, BS</last_name>
    <phone>763-406-4863</phone>
    <email>amussett@nmdp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monzr M. Al Malki, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Arai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Bin Chen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Litzow, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University/St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip McCarthy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State Medical Center, James Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayman Saad, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chitra Hosing, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Be The Match Collection Center Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huy Pham, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

